

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number
WO 03/039598 A1

(51) International Patent Classification⁷: **A61K 45/00**,
31/165, A61P 25/00

(72) Inventors: **RAO, Srinivas, G.**; 11590 Jaguar Ct., San Diego, CA 92131 (US). **KRANZLER, Jay, D.**; 7935 Via Capri, La Jolla, CA 92037 (US).

(21) International Application Number: **PCT/US02/35396**

(74) Agents: **STEFFEY, Charles, E.** et al.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).

(22) International Filing Date:
5 November 2002 (05.11.2002)

(81) Designated State (*national*): **CA**.

(25) Filing Language: **English**

(84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

(26) Publication Language: **English**

(30) Priority Data:
10/014,149 5 November 2001 (05.11.2001) **US**

Published:
— with international search report

(71) Applicant: **CYPRESS BIOSCIENCE, INC.** [US/US];
4350 Executive Drive, Suite 325, San Diego, CA 92121 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SELECTIVE NOREPINEPHRINE SEROTONIN REUPTAKE INHIBITORS FOR TREATING FIBROMYALGIA SYNDROME, CHRONIC FATIGUE SYNDROME AND PAIN**

(57) Abstract: The present invention provides a method of treating, in a mammal, chronic fatigue syndrome (CFS), chronic fatigue syndrome (CFS) that is associated with depression, a combination of chronic fatigue syndrome (CFS) and fibromyalgia syndrome (FMS), fibromyalgia syndrome (FMS) associated with depression, pain and pain associated with depression. The method includes administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof.

WO 03/039598 A1